Secretomic Changes of Amyloid Beta Peptides on Alzheimer's Disease Related Proteins in Differentiated Human SH-SY5Y Neuroblastoma Cells

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2024 Jul 22

PMID 39035166

Authors

Sittiruk Roytrakul

Janthima Jaresitthikunchai

Narumon Phaonakrop

Sawanya Charoenlappanit

Siriwan Thaisakun

Nitithorn Kumsri

Teerakul Arpornsuwan

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease that causes physical damage to neuronal connections, leading to brain atrophy. This disruption of synaptic connections results in mild to severe cognitive impairments. Unfortunately, no effective treatment is currently known to prevent or reverse the symptoms of AD. The aim of this study was to investigate the effects of three synthetic peptides, i.e., KLVFF, RGKLVFFGR and RIIGL, on an AD model represented by differentiated SH-SY5Y neuroblastoma cells exposed to retinoic acid (RA) and brain-derived neurotrophic factor (BDNF). The results demonstrated that RIIGL peptide had the least significant cytotoxic activity to normal SH-SY5Y while exerting high cytotoxicity against the differentiated cells. The mechanism of RIIGL peptide in the differentiated SH-SY5Y was investigated based on changes in secretory proteins compared to another two peptides. A total of 380 proteins were identified, and five of them were significantly detected after treatment with RIIGL peptide. These secretory proteins were found to be related to microtubule-associated protein tau (MAPT) and amyloid-beta precursor protein (APP). RIIGL peptide acts on differentiated SH-SY5Y by regulating amyloid-beta formation, neuron apoptotic process, ceramide catabolic process, and oxidative phosphorylation and thus has the potentials to treat AD.

Citing Articles

Effectiveness of co-cultured Myristica fragrans Houtt. seed extracts with commensal Staphylococcus epidermidis and its metabolites in antimicrobial activity and biofilm formation of skin pathogenic bacteria.

Oo T, Saiboonjan B, Mongmonsin U, Srijampa S, Srisrattakarn A, Tavichakorntrakool R BMC Complement Med Ther. 2024; 24(1):380.

PMID: 39482677 PMC: 11526599. DOI: 10.1186/s12906-024-04675-z.

References

Haddad H, Malone G, Comardelle N, Degueure A, Poliwoda S, Kaye R . Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer's Disease: A comprehensive review. Health Psychol Res. 2022; 10(3):37023. PMC: 9334157. DOI: 10.52965/001c.37023. View

Wood S, Wetzel R, Martin J, Hurle M . Prolines and amyloidogenicity in fragments of the Alzheimer's peptide beta/A4. Biochemistry. 1995; 34(3):724-30. DOI: 10.1021/bi00003a003. View

Fulop L, Zarandi M, Datki Z, Soos K, Penke B . Beta-amyloid-derived pentapeptide RIIGLa inhibits Abeta(1-42) aggregation and toxicity. Biochem Biophys Res Commun. 2004; 324(1):64-9. DOI: 10.1016/j.bbrc.2004.09.024. View

Sims J, Zimmer J, Evans C, Lu M, Ardayfio P, Sparks J . Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023; 330(6):512-527. PMC: 10352931. DOI: 10.1001/jama.2023.13239. View

Sheu F, Mahoney C, Seki K, Huang K . Nitric oxide modification of rat brain neurogranin affects its phosphorylation by protein kinase C and affinity for calmodulin. J Biol Chem. 1996; 271(37):22407-13. DOI: 10.1074/jbc.271.37.22407. View

Gerendasy D, Sutcliffe J . RC3/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes. Mol Neurobiol. 1997; 15(2):131-63. DOI: 10.1007/BF02740632. View

Austen B, Paleologou K, Ali S, Qureshi M, Allsop D, El-Agnaf O . Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide. Biochemistry. 2008; 47(7):1984-92. DOI: 10.1021/bi701415b. View

Yu S, Yan J, Yang Z, Zhao Y, Wang H, Yang X . Metabolic Responses and Pathway Changes of Vero Cells under High-Vitamin B Medium. Vaccines (Basel). 2022; 10(11). PMC: 9693426. DOI: 10.3390/vaccines10111787. View

Agholme L, Lindstrom T, Kagedal K, Marcusson J, Hallbeck M . An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J Alzheimers Dis. 2010; 20(4):1069-82. DOI: 10.3233/JAD-2010-091363. View

10.

Mann M . Can proteomics retire the western blot?. J Proteome Res. 2008; 7(8):3065. DOI: 10.1021/pr800463v. View

11.

Hofhaus G, Attardi G . Lack of assembly of mitochondrial DNA-encoded subunits of respiratory NADH dehydrogenase and loss of enzyme activity in a human cell mutant lacking the mitochondrial ND4 gene product. EMBO J. 1993; 12(8):3043-8. PMC: 413569. DOI: 10.1002/j.1460-2075.1993.tb05973.x. View

12.

Danho W, Swistok J, Khan W, Chu X, Cheung A, Fry D . Opportunities and challenges of developing peptide drugs in the pharmaceutical industry. Adv Exp Med Biol. 2009; 611:467-9. DOI: 10.1007/978-0-387-73657-0_201. View

13.

Horsley J, Jovcevski B, Wegener K, Yu J, Pukala T, Abell A . Rationally designed peptide-based inhibitor of Aβ42 fibril formation and toxicity: a potential therapeutic strategy for Alzheimer's disease. Biochem J. 2020; 477(11):2039-2054. PMC: 7293109. DOI: 10.1042/BCJ20200290. View

14.

Rhein V, Song X, Wiesner A, Ittner L, Baysang G, Meier F . Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A. 2009; 106(47):20057-62. PMC: 2774257. DOI: 10.1073/pnas.0905529106. View

15.

Bardou P, Mariette J, Escudie F, Djemiel C, Klopp C . jvenn: an interactive Venn diagram viewer. BMC Bioinformatics. 2014; 15:293. PMC: 4261873. DOI: 10.1186/1471-2105-15-293. View

16.

Katayama S, Imai R, Sugiyama H, Nakamura S . Oral administration of soy peptides suppresses cognitive decline by induction of neurotrophic factors in SAMP8 mice. J Agric Food Chem. 2014; 62(16):3563-9. DOI: 10.1021/jf405416s. View

17.

Lassek M, Weingarten J, Einsfelder U, Brendel P, Muller U, Volknandt W . Amyloid precursor proteins are constituents of the presynaptic active zone. J Neurochem. 2013; 127(1):48-56. DOI: 10.1111/jnc.12358. View

18.

Handler D, Pascovici D, Mirzaei M, Gupta V, Hosseini Salekdeh G, Haynes P . The Art of Validating Quantitative Proteomics Data. Proteomics. 2018; 18(23):e1800222. DOI: 10.1002/pmic.201800222. View

19.

Haughey N, Bandaru V, Bae M, Mattson M . Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim Biophys Acta. 2010; 1801(8):878-86. PMC: 2907186. DOI: 10.1016/j.bbalip.2010.05.003. View

20.

Villegas S, Njaine B, Linden R, Carri N . Glial-derived neurotrophic factor (GDNF) prevents ethanol (EtOH) induced B92 glial cell death by both PI3K/AKT and MEK/ERK signaling pathways. Brain Res Bull. 2006; 71(1-3):116-26. DOI: 10.1016/j.brainresbull.2006.08.014. View